Sign up
Pharma Capital

Innate Immunotherapeutics to receive cash injection

The halt will remain in place until Monday 20th March 2017.
The raising will involve a book build process

Innate Immunotherapeutics (ASX:IIL) has been granted a trading halt by the ASX, with its shares placed in pre-open.

Innate requested the halt pending a capital raising.

The halt will remain in place until the opening of trade on Monday 20th March 2017, or earlier if an announcement is made to the market.

View full IIL profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.